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ORIGINAL ARTICLE

The Role of BPIFB4 in Immune System and
Cardiovascular Disease: The Lesson
from Centenarians
Francesco Montella a,1, Valentina Lopardo a,1, Monica Cattaneo b, Albino Carrizzo a,c,
Carmine Vecchione a,c, Elena Ciaglia a,**, Annibale Alessandro Puca a,b,*
Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Via Salvatore Allende, 84081,
Baronissi, Salerno, Italy
b
Cardiovascular Research Unit, IRCCS MultiMedica, 20138, Milan, Italy
c
Department of Vascular Physiopathology, IRCCS Neuromed, Pozzilli, 86077, Isernia, Italy
a

Abstract
Recent discoveries have shed light on the participation of the immune system in the physio pathology of the cardiovascular system underpinning the importance of keeping the balance of the ﬁrst to preserve the latter. Aging, along
with other risk factors, can challenge such balance triggering the onset of cardiovascular diseases.
Among several mediators ensuring the proper cross-talk between the two systems, bactericidal/permeabilityincreasing fold-containing family B member 4 (BPIFB4) has been shown to have a pivotal role, also by sustaining
important signals such as eNOS and PKC-alpha.
In addition, the Longevity-associated variant (LAV), which is an haplotype allele in BPIFB4 characterized by 4
missense polymorphisms, enriched in homozygosity in Long Living Individuals (LLIs), has been shown to be efﬁcient, if
administered systemically through gene therapy, in improving many aspects of cardiovascular diseases (CVDs). This
occurs mainly through a ﬁne immune system remodeling across: 1) a M2 macrophage polarizing effect, 2) a favorable
redistribution of the circulating monocyte cell subsets and 3) the reduction of T-cell activation. Furthermore, LAVBPIFB4 treatment induced a desirable recovery of the inﬂammatory balance by mitigating the pro-inﬂammatory factor
levels and enhancing the anti-inﬂammatory boost through a mechanism that is partially dependent on SDF-1/CXCR4
axis.
Importantly, the remarkable effects of LAV-BPIFB4 treatment, which translates in increased BPIFB4 circulating levels,
mirror what occurs in long-living individuals (LLIs) in whom the high circulating levels of BPIFB4 are protective from
age-related and CVDs and emphasize the reason why LLIs are considered a model of successful aging. Here, we review
the mechanisms by which LAV-BPIFB4 exerts its immunomodulatory activity in improving the cardiovascular-immune
system dialogue that might strengthen its role as a key mediator in CVDs.

1. Introduction

C

VDs represent the leading cause of death
worldwide. According to WHO, 17.9 million
people died from CVDs in 2019 (about 32% of global
deaths) [1]. In order to ameliorate the management
of CVDs, a more integrated vision of cardiac biology
is critical to better determine the mechanisms

leading to CVDs onset and progression. Not surprising the cardiovascular system is made up of a
wide range of cells that interoperate generating a
complex network capable in maintaining the entire
organism functionality and integrity. In heart, ventricular and atrial cardiomyocytes represent the
most abundant cell population followed by endothelial cells, ﬁbroblasts, pericytes, smooth muscle

Received 16 November 2021; revised 16 December 2021; accepted 28 December 2021.
Available online 23 December 2021.
* Corresponding author. Fax: þ39089969602.
** Corresponding author. Fax: þ39089969602.
E-mail addresses: eciaglia@unisa.it (E. Ciaglia), apuca@unisa.it (A.A. Puca).
1
These authors contributed equally to this work.
https://doi.org/10.37825/2239-9754.1029
2239-9754/© 2021 Universita di Salerno. This is an open access article under the CC BY 2.5 license (https://creativecommons.org/licenses/by/2.5/).

2

TRANSLATIONAL MEDICINE @ UNISA 2022;24:1e12

cells, adipocytes, mesothelial cells, neuronal cells
and - resident or from circulating blood - immune
cells of both myeloid (monocytes, macrophages,
neutrophils and dendritic cells) and lymphoid origin
(T and B cells) [2]. Even if immune cells represent
the minor population of the heart (between 5% and
10%), their involvement in both physiological and
pathological conditions in heart and their dialogue
with myocytes and non-myocytes cells is deﬁnitely
an interesting ﬁeld of study. Endothelial cells,
smooth muscle cells and pericytes are the major
cellular component of vessels, arteries, and capillaries and interact through a bidirectional interchange of signals and factors with circulating
immune players [3,4]. These intricate cross-talks
maintain the myocardium and vessels homeostasis
and, when unbalanced, lead to several CVDs. This
unbalance occurs during aging thus triggering the
onset of CVDs. The remodeling of the morphological structure of heart and vasculature, the persistent
exposure to risk factors together with the progressive age-associated decline in heart functionality
and integrity, result in several cardiovascular diseases, including atherosclerosis, hypertension, diabetic cardiomyopathy, myocardial infarction, stroke
and others [5]. Compared to elderly people, longliving individuals (LLIs) represent a model of successful healthy aging. LLIs are less prone to be
affected by CVDs thanks to their ability in preserving both immune response and inﬂammatory balance, which are usually lost and/or deteriorated in
the elderly. Here we will discuss the role of the LAV
haplotype in the BPIFB4 gene found enriched in
homozygosity in LLIs and under positive and
balancing selection, in restoring the proper inﬂammatory balance and successfully modulating the
immune system in physio-pathological conditions
directly (or indirectly) related to CVDs. (see Fig. 1).

2. BPIFB4 and its longevity-associated variant:
from the expression in long-living individuals
(LLIs) to the protective mechanisms in disease
2.1. BPIFB4-related immunomodulatory effects in
LLIs
Despite the increase of life expectancy in industrialized populations that occurred in the last century, a sedentary lifestyle, wrong nutritional habits
and exposure to pollution led to an increased incidence of CVD-related morbidity and mortality. The
case of Long-Living Individuals (LLIs) is the unique
model of delaying or avoiding diseases of aging,
mainly CVDs, extending life-span of 40 years in
comparison to their original cohort life expectancy.

While it is true that diet and exercise are impacting
on the ability to reach eighties in good health, there
is no external intervention that correlates with succeeding in reaching extreme ages, such as the
supercentenarian ones (110 years old). Thus, despite
many evidences are pointing to a balanced diet,
such as Mediterranean Diet, which is characterized
by a low glycemic index (GI), a low animal protein
intake, phytochemical compounds (found in vegetables, fruit, red wine, olive oil) as protective towards cancer and cardiovascular diseases [6],
genetic factors may represent a main cause for the
increased average survival rate of LLIs. Indeed, LLIs
are gifted by a genetic signature that allow them to
survive to extreme ages avoiding diseases of aging
[7]. This reﬂects in exceptional longevity occurring
in families, with a reduction of CVDs and overall
mortality among centenarian's offspring and siblings [8e10]. In the recent years GWASs (Genome
Wide Association Studies) have been run on LLIs
and controls to identify genetic variants that confer
either advantage or a disadvantage to reach extreme
ages. LAV-BPIFB4 is a four-missense single-nucleotide polymorphism haplotype of the Bactericidal/
permeability-increasing fold-containing family B
member 4 (BPIFB4) gene that has been found to be
enriched as homozygous genotype in LLIs, thus
protective for human health, in three independent
populations from Italy, Germany and USA [11] with
an allele frequency of 29.5% with respect to the 66%
of the Wild Type (WT) haplotype. LAV homozygous
genotype reaches 14% in centenarians compared to
10% in controls [11e13]. The homozygous genotype
showed a clear correlation with high eNOS phosphorylation in serine 1177 that correlates with high
activity and Nitric Oxide (NO) production in PBMCs
of healthy subjects. Furthermore, an inverse correlation of the homozygous LAV-BPIFB4 was found
with frailty in elderly subjects and accordingly, in
old mice LAV-BPIFB4 gene transfer delayed frailty
progression [13]. BPIFB4 is a secreted protein found
in respiratory secretion, upper airways and proximal trachea [14] with an appreciable expression
also in cardiomyocytes and endothelial cells [15],
PBMCs [16], cardiac pericytes (personal communication) and striatal-derived cell lines [17]. BPIFB4 is
particularly abundant in serum of long-living individuals presumably allowing them to maintain a
proper balance between anti-inﬂammatory and proinﬂammatory mechanisms without encountering
the detrimental remodeling of immune system
usually found in the elderly [18].
The genetic and epigenetic ﬁndings described
above about BPIFB4 and LLIs, gave an impulse to
further scan LLIs for the identiﬁcation of new
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molecules to be candidates for their delaying of
CVD and other age correlated diseases. A cytokines
analysis conducted in a ﬁrst cohort of N ¼ 20 Long
living individuals (LLIs) from Cilento, a rural area of
the South Italy, demonstrated an increase of IL-10
and IL-1RA in the plasma of LLIs compared to
healthy volunteers [19]. From a functional point of
view, we also recently described a peculiar anti-inﬂammatory ability of LLI's plasma. When healthy
monocytes-derived macrophages were differentiated in presence of plasma from LLIs, they acquired
a CD206 þ CD163þ macrophage phenotype, highlighting their M2 anti-inﬂammatory nature.
Furthermore, BPIFB4 protein, found enriched in
LLIs' plasma, was responsible for the M2 polarizing
activity of LLIs' plasma. Indeed, the BPIFB4neutralizing antibody induced a signiﬁcant decrease
in macrophage M2 recovery upon stimulation with
LLIs' plasma [20]. Next, a Multiplex bead-based
immunoassay on LLIs' plasma revealed that other
factors characterized LLIs compared to adult individuals. Among these, thymus and activation
regulated chemokine (TARC)/CCL17 and smallinducible cytokine B10 (IP-10)/CXCL10) cytokines
were the only additional factors enriched in centenarians, thus indicating them as additional key
mediators of successful ageing [21]. The two cytokines are mainly released from myeloid cells: IP-10
is an effector cytokine enhancing host performance
against infectious disease [22]; TARC is implicated
in the T cell recruitment and produced from M2
macrophages as effector molecule that inhibit M1
inﬂammatory macrophages generation [23]. However only TARC seems to be responsible for M2
polarizing action of LLIs plasma as TARC-, but not
IP-10-blocking antibodies were able to rescue the
M2 enrichment in monocyte-derived macrophage
compartment [21].
Taking all the above results in consideration, we
reasoned that the peculiar cytokine proﬁle may
be responsible for the skewed monocytes asset
found in LLIs. Indeed, characterization of circulating monocytes from 52 LLIs (median-age 97)
and 52 healthy volunteers (median-age 55) showed
that the intermediate CD14þþCD16þ monocytes
counts were lower in LLIs compared to control
adults. Conversely, non-classical CD14 þ CD16þþ
monocyte counts, which are M2 macrophage precursors with an immunomodulatory function, were
found signiﬁcantly associated with the LLIs' state
[21].
The enriched subset of non-classical monocytes is
known to actively patrol the vasculature and
remove damaged cells in several disease

3

conditions, thereby aiding tissue healing and the
resolution of inﬂammation [24]. Further, non-classical patrolling monocytes might serve as precursors for protective M2-macrophages during soft
tissue injury [25].
2.2. Molecular events regulating BPIFB4 action
Mechanistic investigations elucidated the signal
transduction pathways by which BPIFB4 protein,
and its LAV-isoform induces pleiotropic effects on
immune system or in presence of cardiovascular
disease to offer protection from age-related
impairment. Among these, we previously reported
that protein kinase R-like endoplasmic reticulum
kinase (PERK), a kinase involved in the unfolded
protein response, exerts the phosphorylation at
Serine 75 of BPIFB4 (that seems to have a cytoplasmatic localization), and its LAV-variant in
endoplasmic reticulum stress response and cellular
homeostasis. This event also allows its interaction
with the 14-3-3 protein and the Heat Shock Protein
90 (HSP-90) resulting in the BPIFB4-14-3-3-HSP90
complex that induces eNOS phosphorylation and
NO production in endothelial cells [26]. To be
noted, the formation of the complex that is paired
with the BPIFB4 serine 75 phosphorylation, is a
peculiarity of LAV-BPIFB4. Consistently, ectopic
expression of LAV-BPIFB4 in HUVEC endothelial
cell lines resulted in the stimulation of NO production due to the activation of the Protein kinase C
alpha (PKCa) signaling. Mechanistically, LAVBPIFB4 augmented Ca2þ mobilization that in turn
increased the translocation of PKCa to the plasma
membrane. Importantly, in the absence of external
Ca2þ, the ability of LAV-BPIFB4 to enhance both
PKCa and eNOS phosphorylation was abolished
[27]. More recently, gene therapy in ApoE knockout
mice with AAV-LAV-BPIFB4 has been described to
reduce the formation of vascular plaques, and this
effect was lost by the co-treatment with AMD3100,
an inhibitor of CXCR4 receptor (a seven transmembrane G-protein-coupled, alpha-chemokine
receptor speciﬁc for SDF-1a), which suggests a
possible involvement in the LAV-BPIFB4 regulation
of calcium via CXCR4-SDF1 pathway [28]. The effects of LAV-BPIFB4 on this axis was valid also in
the brain. Indeed, in a mouse model of Huntington's disease, the LAV-BPIFB4 plays a critical role in
a CXCR4-dependent action, as shown both in vitro
and in vivo, inducing SDF-1 expression from striatal cells and polarizing human microglia to an antiinﬂammatory status in culture. In this context the
ability of LAV-BPIFB4 to ﬁnely shape the M1eM2
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balance of human microglia in part explains its
therapeutic potential [17].

3. The auspicable atheroprotective role of
LAV-BPIFB4 in human patients and in a
mouse model of the disease
3.1. Atherosclerosis physiopathology
Atherosclerosis is a chronic inﬂammatory disease
and it is considered maybe the ﬁrst cause of coronary artery disease and stroke [29]. Generally,
atherosclerosis was considered a cholesterol storage
disease caused by the accumulation of lipoproteins
including LDL in the intimal tissue of arteries
resulting in the continuous growth of fatty inﬁltrates
rich in inﬂammatory leukocytes that macroscopically appear as plaques [30]. Plaque ruptures at the
surface trigger thrombosis with a huge involvement
of platelets [31]. The role of the innate immune
system especially monocytes and macrophages,
together with neutrophils and lymphocytes are also
key for the onset and development of atherosclerosis [32,33]. Resident macrophages in atherosclerotic lesions are continuously exposed to
accumulating lipids and their oxidized derivatives.
Cholesterol clusters and oxidized LDL can induce
monocytes and macrophage to polarize in inﬂammatory cells. Thus, in response to this environment,
macrophages adapt their phenotype to a M1 activation state [34]. M1 macrophages are associated
with symptomatic and unstable plaques, whereas
M2 macrophages are particularly abundant in stable
zones of the plaque and asymptomatic lesions. This
suggests that M2 macrophages are localized within
human plaques and their intrinsic anti-inﬂammatory properties, are primarily associated with plaque
stability [35,36].
3.2. LAV-BPIFB4 role in atherosclerotic process
The balance between the thickness of ﬁbrotic cup
that surrounds the plaque and the inﬂammatory
status determines the stability of the entire system.
An unbalanced environment leads to a break of the
plaque with the high risk of circulating debris and
thrombus with consequential ictus, myocardial
infarction or stroke [37]. In this scenario, LAVBPIFB4 was found to reduce atherosclerotic progression leading the immune system to an anti-inﬂammatory polarization. In an ApoE knockout mice
fed a high-lipid diet, a well-known atherosclerosisprone murine model, it has been demonstrated the
efﬁcacy of LAV-BPIFB4 in contrasting endothelial
dysfunction, plaque progression, inﬂammatory

cytokine release, macrophage shift, and T cell activation. First we observed that LAV-BPIFB4 gene
transfer causes a CXCR4-dependent redistribution
of the two major monocyte subsets with reduced
Ly6Clow subsets and increased circulating
Ly6Chigh cells, common precursor of M2 atheroprotective macrophages [28]. As a result, LAVBPIFB4 gene therapy reduced the proliferation of
Ki-67þ T cell in murine blood. Looking at CD3þ
subset, LAV-BPIFB4 gene decreased the abundance
of proliferating cytotoxic CD8þ T. These effects
were inhibited by the CXCR4 inhibitor AMD3100.
Following a translational approach, we proved that
the healthy phenotype of LLIs can be transferred to
both murine models and cultured human tissues
not only by the delivery of LAV-BPIFB4 gene but
also by a recombinant protein (rhLAV-BPIFB4)
treatment. Indeed, the administration of recombinant protein lead the atherosclerotic patients macrophages to acquire a M2 phenotype, as shown by
the up-regulation of the canonical M2 marker
CD163. Furthermore, the LAV-BPIFB4 recombinant
protein ﬁnely modulated the cytokine secretion
from atherosclerotic vessel after 72 h of culture,
increasing the atheroprotective IL-33 and downregulating pro-inﬂammatory IL-1b and TNF-a. In
this view, LAV-BPIFB4 appears as a promising
immunoregulatory agent in atherosclerosis. Indeed,
LAV-BPIFB4 gene therapy succeeded in the two
primary endpoints: improving endothelial dysfunction and reducing adverse vascular effects in ApoE
knockout mice [28]. More interestingly, from a
clinical point of view, in patients with no subclinical
carotid atherosclerosis, the protein's concentration
was signiﬁcantly higher if compared to patients with
carotid stenosis. Furthermore, genotype stratiﬁcation analysis conﬁrmed that LAV carriers have more
frequently an intima media thickness (IMT) < 2 mm
and had a higher level of protective BPIFB4
compared to WT carriers [28]. Overall these preclinical data proposed LAV-BPIFB4 as relevant
immunomodulatory/immunotherapeutic tool in
Atherosclerotic progression.

4. The role of LAV-BPIFB4 in rescuing heart
functionality in diabetic cardiomyopathy
Diabetic cardiomyopathy is a clinical condition of
myocardial dysfunction that occur in diabetic patients without cardiac risk factors (ie, coronary artery disease, hypertension, valvular complications),
which in turn becomes a risk factor for heart failure
[38,39].
From a metabolic point of view, hyperglycaemia,
hyperlipidaemia and lipotoxicity caused by a lack of
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insulin or insulin resistance trigger mithocondrial
dysfunction due to increased intracellular fatty acid,
enhanced ROS and RNS production. These events
in turn lead to cardiac alterations: 1) cardiomyocytes
death and hypertrophy, 2) cardiac ﬁbrosis associated with impaired ECM degradation by MMPs,
release of TNF, TGF-b, angiotensin II 3)microvascular dysfunction mediated by endothelial damage
(reduced NO signalling) [40]. Pro-inﬂammatory
pathways work synergically with the pathological
mechanisms of diabetic cardiomyopathy leading to
a systemic and cardiac inﬂammatory cell activation,
as shown by the high detrimental levels of IL-1b,
NF-kb, TNF-a, AKT1 and lypoxigenase. At this regard, we have been recently investigated the
immunomodulatory role of LAV-BPIFB4 in diabetic
cardiomyopathy [15] through the SDF-1/CXCR4
axis, known to be involved in the development of
cardiac dysfunction underpinning diabetic cardiomyopathy [41,42] and reported as the mechanisms
through which LAV-BPIFB4 induces M2 macrophage polarization in atherosclerosis [28]. Both in
human cardiac cells and in validated db/db mice
model, the overexpression of LAV-BPIFB4 had a
desirable effect in restoring the affected cardiac
functionality compromised by the diabetes-induced
damage. Indeed, LAV-BPIFB4-treated mice showed
an improved systolic function and capillaries density coupled with the increased expression of
MyHC-a, involved in the contractile property of
myocytes and endothelial function, and reduction in
heart lipid content. The in vivo co-treatment with
LAV-BPIFB4 and an antagonist of CXCR4 (ie, AMD070) prevented the resolutive effect of LAV-BPIFB4
conﬁrming that this peculiar isoform of BPIFB4
operates through SDF-1/CXCR4 axis. LAV-BPIFB4
in vitro treatment and in vivo gene therapy were
also able to induce the expression of SDF-1
respectively in human CD14 þ CD16þ intermediate
monocytes from type 2 diabetic patients and in peripheral blood and heart of diabetic mice. In concert
with the beneﬁcial effect of SDF-1 on heart and the
ability of BPIFB4 in promoting the SDF-1 expression
on monocytes and in db/db mice heart, LAV-BPIFB4
might be considered as an immunoregulatory driver
in CVDs (i.e. diabetic cardiomyopathy) considering
its inﬂuence on SDF-1 expression that in turn could
exhibit its protective role.

5. BPIFB4 as a prognostic factor in COVID-19
Cardiovascular diseases constitute one of the most
common comorbitities (with a prevalence of 8%
from independent studies) [43,44] in patients infected with Severe acute respiratory syndrome
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coronavirus 2 (SARS-CoV-2), the Coronaviridae
family virus causing COVID-19 pandemic. CVDs
are doubly implicated in COVID-19 both due to the
high risk of COVID-19 in pre-existing CVDs patients and on account of the cardiovascular implications of the infection among patients with
COVID-19 [45]. Brieﬂy, the viral spike protein binds
the ACE2 receptor expressed on host cells and,
following the entry and replication, it triggers an
uncontrolled immune response to which the immune system responds with an inadequate virus
clearance and an inﬂammatory imbalance that
conversely leads to the sadly known “cytokine
storm”. The Angiotensin-converting enzyme 2 receptor is not only expressed on nasal epithelial cells,
lungs, and bronchial branches (making ACE2 receptor the key factor for SARS-CoV-2 infection) but
also on cardiomyocytes, cardioﬁbroblasts, pericytes,
coronary endothelial cells and cardiac muscle cells
[46]. The almost ubiquitous presence of ACE2 receptor on different cardiac cell subtypes might
explain the potential involvement of the cardiovascular system in SARS-CoV-2 infection and the
related complications including myocarditis, heart
failure, cardiomyopathy, myocardial infarction, and
thromboembolic events [47]. In addition, the dysregulation of cardiac immune cells unabled to
counteract the infection and the cytokine storm
established the need to investigate successful immunotherapies for COVID-19 and cardiovascular
complications. Among the others (recently reviewd
by Xie et al., 2021, [48]), BPIFB4 seems to be a valid
prognostic marker for COVID-19 being its low
circulating levels in SARS-CoV-2-positive individuals (with respect to LLIs and controls groups)
that is further reduced in high-grade patients [49].
In vitro experiments on PBMCs have showed a
biphasic immune response mediated by recombinant LAV-BPIFB4 (rLAV-BPIFB4) that in the ﬁrst
phase of the infection induced a hyperactivation of
CD4þ and CD8þ lymphocytes that decreases in the
ending phase of the treatment demonstrating that
this longevity-associated variant has a considerable
immune shaping activity. In advanced heart failure,
the chronic activation of lymphocytes is responsible
of cardiovascular insult [50]. Hence the two-phase
immune response induced by rhLAV-BPIFB4 in
COVID-19 context might be crucial in remodeling
the perpetuated lymphocytes activation involving in
heart failure. Coupled with this dual immunomodulatory activity on lymphoid compartment, rhLAVBPIFB4 was able to modulate the PBMCs microenvironment inducing the reduction of MCP-1 levels
accompanied by higher amount of IL-1b and IL-18
required for the immune response against the virus.
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MCP-1 is well-known for its role in regulating
monocytes chemotaxis into the situ of inﬂammation
and T-lymphocytes differentiation both in health
and disease [51]. In light of that, MCP-1 (and its
binding to cells expressing CCR2) has a pivotal role
in atherosclerosis and myocardial infarction [52,53].
Mediators of CVDs can induce a signiﬁcant release
of MCP-1 by endothelial cells and smooth muscle
cells of vascular wall promoting monocyte diapedesis into the endothelial space and the accumulation of lipid foam cells in the arterial wall. Since the
crucial role of endothelial cells in COVID-19 and the
known role of LAV-BPIFB4 in modulating the
endothelial function [11,54], BPIFB4 might exert its
protective effect in endothelium dysfunction occurring during inﬂammatory conditions also opposing
high levels of MCP-1.
Compared to inﬂammaging occurring in elderly
people, LLIs maintain a ﬁne balance between antiinﬂammatory and pro-inﬂammatory mechanisms
and the Longevity-associated variant of BPIFB4 has
proven to ensure the adequate inﬂammatory
response in the above-investigated experimental
setting of COVID-19. Its potential role as positive
prognostic marker in COVID-19 is also conﬁrmed
by a better response to SARS-CoV-2 infection
registered in centenarians of Italian region [55].

6. The involvement of BPIFB4 in immune
response to prolonged infections
Bacteria, fungi, viruses, and parasites can infect
the organism in diverse sites such as lung, bloodstream, renal and genitourinary tracts. Stimulation
of pattern recognition receptors (PRRs; ie, TLRs,
NLRs, CLRs) by molecular patterns from microbial
components named PAMPs (ie, LPS) triggers the
innate immune response through the activation of
signaling pathways (ie, NF-kb, JNK, ERK, inﬂammasome activation) that elicit the initial hyper-inﬂammatory response (made up of an intricate
interplay of pro-inﬂammatory and anti-inﬂammatory processes) followed by a considerable immunesuppresion phase [56,57] leading to a generalized
dysregulation of the immune response. Neutrophils
are systematically activated showing both an
impaired migration in infection sites and increased
release of immature neutrophils in blood stream
after augmented granulopoiesis process [58].
Monocytes from septic patients show decreased
HLA-DR and CD86 levels coupled with decreased
expression of CD163 and increased expression of
CD206 receptors [59,60]. Taken together these data
suggest a dysregulated antigen presentation activity
accompanied by higher propensity to acquire an

anti-inﬂammatory phenotype demonstrating a partial anergy in monocytes during uncontrolled host
response to infections. Monocytes migrate rapidly
during acute inﬂammation and can differentiate into
macrophages or dendritic cells [61]. Dendritic cells
undergo a caspase-3-mediated apoptosis and an
excessive activation due to systemic circulation of
PAMPs resulting in a limited ability of DCs in
priming T cell response [62]. If macrophages acquire
a M1-like phenotype aimed to eliminate the pathogens in the early phase of infections, they quickly
switch in a state of damaging tolerance towards the
infectious agent (eg, LPS) leading to T cell apoptosis
and the suppression of Th1 response [63]. As above
mentioned, BPIFB4 is particularly abundant on olfactory epithelium, in respiratory secretions, upper
airways and proximal trachea [64]. Seen its expression in several hypothetical site of infection, its role
as both defensine and immune-driver has been
explored. LPS-infected human CD14þ monocytes
and induced-dendritic cells have demonstrated to
be less prone to release TNF-a and IL-1b when pretreated with LAV-BPIFB4 [20] re-conﬁrming the
ability of the protein variant in balancing the inﬂammatory microenvironment. At the same time,
monocyte-derived DCs exposed to LAV-BPIFB4
secreted more anti-inﬂammatory factors as IL-10
and TGF-b in response to LPS and higher expression of CD11b marker tolerogenic. These data suggest LAV-BPIFB4 is able to blunt the proinﬂammatory response to LPS in monocytes and
dendritic cells, the major innate immune cells
involved in struggling infections.
Due to the diminished immune system efﬁciency
(termed immune senescence), the persistence of a
chronic low-grade pro-inﬂammatory state and
comorbidities occurrence [65], elderly people
display a decreased ability in clearing infections and
in managing their clinical complications. In agreement with the above-mentioned in vitro observations, long-living individuals show a peculiar
cytokine proﬁle enriched with IL-10 and IL-1RA
compared to healthy adults. This ﬁnding could lay
the basis to speculate that the strong anti-inﬂammatory environment of LLIs is able to counterbalance the low-grade inﬂammatory background that
makes elderly people less able to ﬁght against
infections.

7. A putative senotherapeutic action for LAVBPIFB4
It is widely known that the incidence of CVDs
increases with aging [66]. This higher prevalence of
CVDs in elderly population has been linked to
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several events among which a paradox has been
contemplated as the major hallmark of ageing.
Indeed, the gradual decline in immune cells function and abundance (hence insufﬁciency and dysregulation, termed immunosenescence, [67])
triggers a persistent chronic low-grade inﬂammation (hence over-reaction, termed inﬂammaging,
[68]). Anatomically, the thimic involution occurring
during aging produces ineffective central tolerance
and reduced thymopoiesis leading to increased
autoimmune responses and decreased efﬁciency in
ﬁghting infections. In addition, senescent cells
release SASP factors (i.e., cytokines, chemokines,
matrix metalloproteases, growth factors) inﬂuencing
neighbouring cells and contributing to inﬂammaging. Even if acute cellular senescence has a beneﬁcial role in heart regeneration and development [69],
emerging data have proven that during aging the
long-term accumulation of senescent cardiovascular
and immune cells lays the basis for pathogenesis of
several CVDs, such as hypertension [70], atherosclerosis [71,72] and heart failure [73]. In this regard,
the role of LAV-BPIFB4 in delaying or halting
immunosenescence has been investigated.
As the intricate cross-talk between cardiac cells
and immune cells preserves cardiovascular homeostasis, immune senescent cells could contribute
to enhance CVDs along with senescent myocytes,
mainly in elderly [74,75]. To this aim, our data
showed AAV-LAV-BPIFB4 gene transfer may
counteract immunosenescence and vasculature
aging in old mice [76]. Firstly, we found a signiﬁcant
decrease in SA-b-Gal activity in CD11b þ myeloid
cells isolated from 26 months C57BL/6J mice
receiving the AAV-LAV-BPIFB4 compared to oldGFP mice. Furthermore, plasma of AAV-LAVBPIFB4 mice showed a better SASP factor proﬁle
made up of lower levels of IL-1b and higher IL-10
levels. As immune senescent cells can regulate the
myocardial microenvironment also by directly
modulating myocytes senescence [77], these data
suggest LAV-BPIFB4 gene transfer may be a valid
tool in educating the senescence phenotype associated to worse CVDs outcomes. Since senescent cells
release SASP factors in a non-cell autonomous
manner eliciting a response in surrounding cells
and tissues [78], aortas from old-mice showed a
higher percentage of SA-b-Gal positive area that
was signiﬁcantly reduced in response to AAV-LAVBPIFB4 in vivo treatment. Collectively, these data
demonstrated LAV-BPIFB4 could shape the inﬂammatory cytokine plethora induced by senescence that in turn leads to tissue damage and
ageing.
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Recently, senescence and inﬂammation in ageing
have been associated to NAD þ levels decline
attributable
to
higher
expression
of
NAD þ consuming enzymes, including CD38, in
immune cells compartment [79]. Our data showed
that AAV-LAV-BPIFB4 treatment induces a recovery in NAD þ levels comparing to young and untreated mice. This data reached a translational value
considering that LLIs showed a statistically signiﬁcant increase of plasmatic NAD þ levels with
respect to old healthy control demonstrating LAVBPIFB4 can positively interfere with the NAD þ related ageing process in vivo. Moreover, LLIs genotype analysis proved that LAV-carriers are characterized by higher levels of NADþ in comparison
to WT-carriers. In this light, this could be added to
all those reason why LLIs and LAV-BPIFB4 carriers
are less inclined to develop age-related diseases.
Moreover, the AAV-LAV-BPIFB4 treatment seemed
to provide a very efﬁcient catabolic activity in the
spleen of aged mice. Indeed, AAV-LAV-BPIFB4
leads to the enrichment of senescent cells in spleen
coupled with the increase of active NK1.1 þ CD69þ
cells among total splenocytes suggesting a role of
LAV-BPIFB4 in clearing senescent cells through
NK-induced cytotoxicity. Remarkably, AAV-LAVBPIFB4 gene transfer also increased the M2 proresolving macrophages compartment in the spleen,
reduced the amount of both spleen-resident CD38þ
macrophages and CD38þ pro-inﬂammatory monocytes and mitigated the splenic inﬂammatory
microenvironment (generating a milieu made up of
lower levels of IL-1b, IL-6, IFN-g and higher levels
of IL-10).
To improve matters, the positively arranged
milieu of AAV-LAV-BPIFB4 mice was capable to in
vitro shaping the immune asset of a monocyte/
macrophage cell line by inducing the acquisition of
M2-like phenotype and the internalization (and not
the surface upregulation) of CD38 marker demonstrating AAV-LAV-BPIFB4 may be able in counteracting the non-autonomous effect by which
senescence is gained by non-senescent cells. The
role of LAV-BPIFB4 in enhancing the catabolic activity of the main hemocateretic organ and in
restoring the activation of clearance mechanisms
lost during ageing could be very beneﬁcial in the
reduction of cardiovascular senescence cell burden
profoundly connected to a variety of CVDs [80].
Moreover, the anti-inﬂammatory microenvironment
opposing the SASP, the M2 polarizing effect (that in
heart have pro-ﬁbrotic and pro-angiogenic properties, [81]), the modulation of CD38 expression and
NAD þ activity (well known to be involved in

Study Model

Human PBMCs

PBMCs from type 2 diabetic patients;
db/db mice model

LPS-infected human CD14þ monocytes;
LPS-infected induced-dendritic cells

ApoE knockout mice (ApoE /)
BMCs from atherosclerotic patients
Organotypic cultures of human
atherosclerotic vessels

26 months C57BL/6J mice
Plasma from long-living
individuals and aged donors

Pathology

COVID-19

Diabetic
cardiomyopathy

Infections

Atherosclerosis

Immunesenescence

In vivo, AAV-LAV-BPIFB4
gene therapy

In vivo, AAV-LAV-BPIFB4
gene therapy
In vitro, human recombinant
LAV-BPIFB4
Ex vivo and in vitro, human
recombinant LAV-BPIFB4

In vitro, human recombinant
LAV-BPIFB4
In vivo, AAV-LAV-BPIFB4
gene therapy
In vitro, human recombinant
LAV-BPIFB4
In vitro, human recombinant
LAV-BPIFB4

In vitro, human recombinant
LAV-BPIFB4

Type of study

Table 1. The pleiotropic immunomodulatory activity of LAV-BPIFB4 in CVDs.

Inﬂammatory balance recovery: reduction of
pro-inﬂammatory TNF-a and IL-1b levels
Induction of anti-inﬂammatory IL-10 and
TGF-b factors and expression of CD11b
tolerogenic marker
Reduction of the atherogenic process and plaque
stabilization
Peripheral monocyte redistribution and polarization
Increase of ‘classical’ Ly6Chigh and decrease
of ‘non-classical’ Ly6Clow circulating monocytes
and shifting effect on splenic macrophages
towards the pro-resolving M2 phenotype.
Induction of increased peripheral blood levels
of IL-23 and IL-27, key suppressor cytokines
in atherosclerosis
Reduction of the abundance of proliferating
cytotoxic CD8þ T cells
Macrophage polarization towards the alternative
M2 anti-inﬂammatory state
Less levels of pro-inﬂammatory IL-1b and TNF-a
and increased atheroprotective IL-33 levels
Reduction of senescence in:
CD11b þ myeloid cells
Aortas
Increase of NAD þ levels and reduction of
CD38 activity
Improvement of splenic catabolic activity: increase
of active NK1.1 þ CD69þ;
increase of M2 pro-resolving macrophages;
reduction of spleen-resident CD38þ macrophages
and CD38þ pro-inﬂammatory monocytes
Modulation of SASP factors in plasma and
spleen milieu
Increase of NAD þ levels in LLIs

Induction of biphasic immune response to
SARS-CoV-2: starting hyperactivation
of CD4þ and CD8þ lymphocytes
followed by its reduction in the
ending phase of the treatment
Modulation of PBMCs microenvironment: reduction
of pro-inﬂammatory MCP-1 levels and increase
of anti-inﬂammatory IL-1b and IL-18
Induction of SDF-1 expression, through the
CXCR4 signaling

LAV-BPIFB4 effect

[28]

[76]

Viable therapy in
counteracting both
vascular and immune
sides of atherosclerosis

Valid senotherapeutic
tool in delaying immune
system senescence

[19]

[15]

[49]

Valid biomarker in
COVID-19 prognosis

Promising immuno
therapeutical approach
in treating diabetic
cardiomyopathy
Regulatory factor of
myeloid cells-related
immune response

Ref

Potential applications
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Heart
LAV-BPIFB4

•
•
•

Remodelling of the diabetes-induced damaged heart
Haemodynamic and structural improvement
Restoration of the affected cardiac functionality

•
•
•

Rescue of an anti-inflammatory status
M2 macrophages polarizating effects
Enrichment of the Non Classical-patrollling
monocytes
Release of anti-inflammatory cytokine:
IL-10, IL-1RA, TARC, IP-10, IL-17, IL-23
Regulated dynamics of CD38+
immunosenescent cells

Immune System

•
•

Healthy
Ageing

Endothelium
•
•
•

Atherosclerotic plaque reduction
Nitrogen oxide production
Reduced endothelial dysfunction

Graphical summary of LAV-BPIFB4 effects on cardiovascular and immune system
Fig. 1. LAV-BPIFB4 effects on cardiovascular and immune system. LAV-BPIFB4 can inﬂuence the activity of immune cells in atherosclerosis, diabetic
cardiomyopathy, and cardiovascular complications mainly by remodelling heart, enhancing anti-inﬂammatory circuits and prevent endothelium
dysfunction.

several CVDs, as hypertension, arrhythmia, coronary heart disease, [82]) elect LAV-BPIFB4 as valid
tool in delaying heart senescence as well done in
immune system.
As the excessive senescent cells accumulation
represents one of the pillars of ageing and chronic
diseases [83,84], AAV-LAV-BPIFB4 treatment
showed both catabolic and senotherapeutic effects
by succeeding in proper eliminating and shaping
senescent cells. Seen the role of LAV-BPIFB4 in
rejuvenating both the immune and cardiac senescent compartment and considering the involvement
of CD38-dependent NADase activity in cardiac
myocytes and endothelial cells [85], a potential role
of LAV-BPIFB4 in reducing the CD38 activity in
myocyte cells is plausible. Moreover, the peculiar
attitude of LLIs in stemming the senescence process
is another lesson to be considered for better
exploring ageing and age-related disease. In this
perspective, LAV-BPIFB4 could be a useful senotherapeutic agent in heart and immune system
ensuring the homeostasis lost with ageing.

8. Conclusions
A plethora of research papers have been clearly
documented the activation of immune pathways
and the involvement of both cellular and soluble
immune mediators in the onset, progression and
prognosis of the main cardiovascular diseases. Long
living individuals are a precious source of

knowledge from which to draw not merely the secrets of healthy ageing but mainly all the mechanisms through which a correct homeostasis between
immune and cardiovascular system can be reached.
In the past years, we discovered that longevityassociated variant of the BPIFB4, a protein
belonging to the innate immune compartment due
to its antimicrobial properties, also corrects endothelial dysfunction, atherosclerosis and immunesenescence by establishing in part a protective
immune response. Looking for both prognostic
biomarkers as well as for innovative immunomodulatory tools, here we deeply reviewed the role of
LAV-BPIFB4 in positively inﬂuencing the activity of
immune cells in atherosclerosis, diabetic cardiomyopathy, and cardiovascular complications to prolonged or aberrant infections (as summarized in
Table 1).
The ability of LAV-BPIFB4 to limit CVD progression and fate by a) skewing M2 response, b)
reducing CD8þT cell reactivity, c) enhancing regulatory circuits in plasma (IL-10, IL-1RA), d) reducing
CD38þNADase expression in immune cells, e)
establishing a dual response to LPS stimulation
(both enhancing and dampening) and f) enrichment
of the pool of protective patrolling monocytes might
suggest the best way to tune the immune system in
age-related conditions (Fig. 1). Indeed, as immune
cell functions that are deleterious in heart and vessels may be required for mounting an efﬁcient host
response against any kinds of insults and stressors;
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in future immunomodulatory signals, such as LAVBPIFB4, more than non-speciﬁc immunosuppressants may constitute a desirable valid option in the
management of CVDs.
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